C-Reactive Protein Concentrations Among Crop and Dairy Farmers with Stable Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.3889/oamjms.2017.140Keywords:
markers of inflammation, COPD, farmers, respiratory symptoms, spirometryAbstract
AIM: To assess the mean serum C-reactive protein concentrations among farmers and office controls, and further examined its relation to exposure duration, smoking habit, as well as presence or absence of COPD.
METHODS: A cross-sectional survey was performed including examined group (EG), composed of agricultural workers (87 crop - EG1 and 83 dairy farmers - EG2), and control group (CG) composed by 80 office workers. Evaluation of subjects included a questionnaire on chronic respiratory symptoms, lung function tests, COPD diagnostics, and measurement of CRP serum concentrations.
RESULTS: Serum CRP concentrations were raised in stable COPD patients independent of smoking habit or exposure duration. The mean CRP serum concentrations were higher in the subjects of EG1 and EG2 compared with those in CG, but without statistical significance. This count for mean CRP serum concentrations in subjects of EG1 and EG2 exposed more than 20 years and for those in smokers in all three groups as well. The mean CRP serum concentrations were significantly higher in subjects with COPD within EG1 (P=0.049) and EG2 (P=0.040), while those in CG were not.
CONCLUSION: Data obtained suggest that systemic inflammation is present in farmers with COPD and CRP is an important biomarker in COPD in means of reflecting disease severity and prognosis of exposed farmers.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Barnes PJ. Medical progress: chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-80. https://doi.org/10.1056/NEJM200007273430407 PMid:10911010
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672-88. https://doi.org/10.1183/09031936.03.00040703 PMid:14582923
Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1218-24. https://doi.org/10.1164/rccm.2202023 PMid:12403691
Noguera A, Busquets X, Sauleda J, et al. Expression of adhesions molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1664-8. https://doi.org/10.1164/ajrccm.158.5.9712092 PMid:9817722
Aaron et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respiratory Research. 2010;11:41. https://doi.org/10.1186/1465-9921-11-41 PMid:20412595 PMCid:PMC2874769
Sin DD, Lacy P, York E, et al. Effects of fluticasone on systematic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760–5. https://doi.org/10.1164/rccm.200404-543OC PMid:15229100
Aksu F, Çapan N, Aksu K, Ofluoğlu R, Canbakan S, Yavuz B, Akin KO. C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. J Thorac Dis. 2013;5(4):414-421. PMid:23991296 PMCid:PMC3755654
Agustà A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007;4:522-5. https://doi.org/10.1513/pats.200701-004FM PMid:17878464
Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:26-33. https://doi.org/10.1513/pats.200408-039MS PMid:16113466
Sin DD, Man SF. Biomarkers in COPD: are we there yet? Chest. 2008;133:1296-8. https://doi.org/10.1378/chest.08-0455 PMid:18574284
de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902-7. PMid:16455829
Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61:17-22. https://doi.org/10.1136/thx.2005.041996 PMid:16055618 PMCid:PMC2080712
Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61:23-8. https://doi.org/10.1136/thx.2005.042200 PMid:16143583 PMCid:PMC2080714
Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-53. https://doi.org/10.1136/thx.2006.059808 PMid:16738034 PMCid:PMC2104755
Danesh J, Muir J, Wong YK, et al. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999;20:954-9. https://doi.org/10.1053/euhj.1998.1309 PMid:10361047
Minette A. Questionnaire of the European Community for Coal and Steel (ECSC) on respiratory symptoms. 1987 - Updating of the 1962 and 1967 questionnaires for studying chronic bronchitis and emphysema. Eur Respir J. 1989;2:165-177. PMid:2703044
European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Respiratory Health Survey (ECRHS). Eur Respir J. 1996;9:687-695. https://doi.org/10.1183/09031936.96.09040687
World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva: WHO, 1998.
Smoking Pack-Years. Available from: http://smokingpackyears.cm/calculate. Accessed 15 June 2017.
US Department of Health and Human Services. The health consequences of smoking: chronic obstructive pulmonary disease. A report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office of the Assistant for Health, Office of Smoking and Health. DHHS Publication No. 84-50 205,1984.
Quajner PhH, ed. Standardization of Lung Function Tests - 1993 Update. Report Working Party for the European Community for Steel and Coal. Official Statement of the European Rrespiratory Society. Eur Rrespir J. 1993;16(l):1-100.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2017 Update. Available at: http://www.goldcopd.org/.
Roberts LW, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of Four Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Clinical Chemistry. 2000;46(4):461-468. PMid:10759469
O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax. 2006;61:448-454. https://doi.org/10.1136/thx.2004.024463 PMid:16648353 PMCid:PMC2111192
Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653. https://doi.org/10.1056/NEJMoa032158 PMid:15215480
Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1b - 511 single nucleotide polymorphism. Am J Clin Nutr. 2005;82:1059-1064. PMid:16280439
Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758-762. https://doi.org/10.1016/S0002-9343(03)00185-2
Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet. 2009;10:23. https://doi.org/10.1186/1471-2350-10-23 PMid:19272152 PMCid:PMC2660301
Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006;61:10-16. https://doi.org/10.1136/thx.2004.034181 PMid:16284220 PMCid:PMC2080698
Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008-1011. https://doi.org/10.1164/ajrccm.164.6.2010067 PMid:11587987
Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170:1286–1293. https://doi.org/10.1164/rccm.200406-754OC PMid:15374843
Piehl-Aulin K, Jones I, Lindvall B, et al. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration. 2009; 78: 191–196. https://doi.org/10.1159/000207793 PMid:19270439
Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824. https://doi.org/10.1136/thx.51.8.819 PMid:8795671 PMCid:PMC472555
Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170:879-882. https://doi.org/10.1164/rccm.200310-1404OC PMid:15271696
Shin KC, Chung JH, Lee KH. Effects of TNF-a and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. Korean J Intern Med. 2007;22:249-255. https://doi.org/10.3904/kjim.2007.22.4.249 PMid:18309683 PMCid:PMC2687660
Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31:492-501. https://doi.org/10.1183/09031936.00074807 PMid:18310396
Schane RE, Woodruff PG, Dinno A, et al. Prevalence and risk factors for depressive symptoms in persons with chronic obstructive pulmonary disease. J Gen Intern Med. 2008;23:1757-1762. https://doi.org/10.1007/s11606-008-0749-z PMid:18690488 PMCid:PMC2585678
Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099-2107. https://doi.org/10.1378/chest.128.4.2099 PMid:16236861
Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-9. https://doi.org/10.1161/01.CIR.0000056767.69054.B3
Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758-62. https://doi.org/10.1016/S0002-9343(03)00185-2
Kocabas A, Hancioglu A, Turkyilmaz S, et al. Prevalance of COPD in Adana, Turkey (BOLD-Turkey Study). Proc Ame Thorac Soc. 2006;3:A543.
Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207-14. https://doi.org/10.1164/rccm.200709-1356OC PMid:18310480
Miniati M, Monti S, Bottai M, et al. Prognostic value of C-reactive protein in chronic obstructive pulmonary disease. Intern Emerg Med. 2011;6:423-30. https://doi.org/10.1007/s11739-011-0520-z PMid:21249472
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
